Ensocell Raises $16.3M to Discover New Drug Targets Using Single-Cell Genomics

Ensocell, the Cambridge-based biotechnology company, has raised $16.3 million in funding backed by OMX Ventures and Sofinnova Capital to develop its proprietary platform for identifying disease intervention points at single-cell resolution. The capital will be used to advance the company's computational and experimental capabilities, expand its team, and progress its pipeline of novel therapeutic targets into early drug discovery.

Ensocell was founded in Hinxton, Cambridgeshire — the home of the Wellcome Sanger Institute and a cluster of genomics-driven life science companies — with a focus on applying single-cell and spatial genomics technologies to the challenge of drug target identification. The company's approach addresses a fundamental problem in therapeutic development: most drug targets are identified by studying cells in bulk, which averages out the biological signals from millions of individual cells and obscures the specific subpopulations — rare cell types, transitional states, or spatially distinct populations — that may be causally relevant to disease.

Ensocell's platform analyses single-cell and spatial transcriptomics data to map the cellular landscape of diseased tissue at high resolution, identify intervention points that are not visible in bulk analyses, and prioritise targets with the strongest biological rationale for therapeutic relevance. The company focuses on diseases where conventional target discovery has been limited by the inability to resolve cellular heterogeneity, and where single-cell approaches can provide a genuinely differentiated view of disease biology.

The broader single-cell genomics sector has grown rapidly since the development of high-throughput single-cell RNA sequencing technologies in the mid-2010s, and the field is now maturing into a commercial stage where its insights can be translated into drug discovery programmes. Ensocell sits at this translational frontier, combining the analytical depth of academic genomics with the target identification and validation rigour required for pharmaceutical partnering and internal pipeline development.

The funding will support Ensocell in building out its target portfolio, deepening its data generation and computational infrastructure, and establishing partnerships with pharmaceutical companies seeking to apply single-cell biology to their drug discovery pipelines.

Sources

• PitchBook — Ensocell company profile and funding
• Crunchbase — Ensocell Therapeutics profile